Nicotine as an Antiepileptic Agent in ADNFLE: An N‐of‐One Study

Purpose: To test nicotine patch treatment for a patient with a defined mutation for autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) whose seizures were refractory to standard antiepileptic therapy. Methods: Open and double‐blind trials of nicotine patches in an “n‐of‐one” study. The doub...

Full description

Saved in:
Bibliographic Details
Published inEpilepsia (Copenhagen) Vol. 44; no. 9; pp. 1238 - 1240
Main Authors Willoughby, John O., Pope, Kenneth J., Eaton, Vaughn
Format Journal Article
LanguageEnglish
Published 350 Main Street , Malden , MA 02148 , U.S.A Blackwell Science Inc 01.09.2003
Blackwell
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Purpose: To test nicotine patch treatment for a patient with a defined mutation for autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) whose seizures were refractory to standard antiepileptic therapy. Methods: Open and double‐blind trials of nicotine patches in an “n‐of‐one” study. The double‐blind trial comprised periods during which either placebo or nicotine patches were each used for three periods of 2 weeks, randomized in a double‐blind manner. Results: In an open study, nicotine patches reduced seizures from 1.65 ± 2.36 to 0.01 ± 0.0 seizures per day (p < 0.0001). In a double‐blinded placebo‐controlled phase, the average frequency of seizures on nicotine versus placebo was 0 ± 0 versus 0.56 ± 1.14 seizures per day (p < 0.0001). Conclusions: Nicotine patches may be of benefit to some individuals with ADNFLE.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
content type line 23
ObjectType-News-5
ObjectType-Case Study-4
ObjectType-Feature-1
ObjectType-Report-3
ISSN:0013-9580
1528-1167
DOI:10.1046/j.1528-1157.2003.58102.x-i1